

Updated on October 6, 2017

Friday, 24 November

17:50-18:30

Plenary Hall

Plenary Lecture 1

Moderator: Ian M. Gould (United Kingdom)

HUMA Lecture:

β -Lactamases as we see them today

Karen Bush (United States)

08:50-09:30

Plenary Hall

Plenary Lecture 2

Moderator: Po-Ren Hsueh (Taiwan)

Novel antibiotics on the horizon

David M. Livermore (United Kingdom)

09:30-10:00

Plenary Hall

Keynote Lecture 1

Moderator: Karen Bush (United States)

Chlorhexidine bathing and nasal decolonisation to prevent infection and reduce antibiotic resistant pathogens

Susan S Huang (United States)

09:30-10:00

Room 201ABC

Keynote Lecture 2

Moderator: Pei-Jer Chen (Taiwan)

Risk stratification and treatment of chronic Hepatitis B: towards the eradication of Hepatitis B virus infection

Jia-Horng Kao (Taiwan)

09:30-10:00

Room 201DEF

Keynote Lecture 3

Moderator: David M. Livermore (United Kingdom)

In "CAST" we trust – but which of the many?

Gunnar Kahlmeter (Sweden)

09:30-10:00

Room 102

Keynote Lecture 4

Moderator: Lionel Ari Mandell (Canada)

Update of pneumonia guidelines: Japan vs. Global

Shigeru Kohno (Japan)

10:30-12:00

Plenary Hall

Symposium 1

Control of carbapenemase producing *Enterobacteriaceae* (CPE)

Co-organised by the Society of Infectious Disease (Singapore)

Moderators: David Chien Boon Lye (Singapore); Jiunn-Jong Wu (Taiwan)

- SP 1-1** **CPE: the antimicrobial stewardship approach**
Wen-Chien Ko (Taiwan)
- SP 1-2** **CPE: the infection control approach**
Vincent Cheng (Hong Kong)
- SP 1-3** **CPE: treatment options**
David Chien Boon Lye (Singapore)

10:30-12:00

Room 201ABC

Symposium 2

MRSA: global epidemiology and treatment

Co-organised by the ISC MRSA Working Group

Moderators: Dale Fisher (Singapore); Chun-Hsing Liao (Taiwan)

- SP 2-1** **Global epidemiology of MRSA: how community acquired-MRSA impacts on clinical practice?**
Shey-Ying Chen (Taiwan)
- SP 2-2** **Treatment and eradication of community acquired-MRSA**
Ian M. Gould (United Kingdom)
- SP 2-3** **New agents for MRSA: recently released or in the pipeline**
Paul Tulkens (Belgium)
- SP 2-4** **Livestock associated-MRSA epidemiology**
Geoffrey Coombs (Australia)

10:30-12:00

Room 201DEF

Symposium 3

Nontuberculous Mycobacteria (NTM)

Co-organised by the ISC Mycobacterial Working Group and Japanese Society of Tuberculosis (JSTB)

Moderators: Bijie Hu (China); Feng-Yee Chang (Taiwan)

- SP 3-1** **Epidemiology: global vs. Asian**
Kozo Morimoto (Japan)
- SP 3-2** **Species versus subspecies: clinical implications**
Won-Jung Koh (Korea)
- SP 3-3** **Treatment of NTM infections**
Ting-Shu Wu (Taiwan)

10:30-12:00

Room 102

Symposium 4

Vascular access: problems and solutions

Moderators: Yoshio Takesue (Japan); Yu-Hui Chen (Taiwan)

- SP 4-1 **Epidemiology and impact of peripheral line associated complications**
Keita Morikane (Japan)
- SP 4-2 **Epidemiology and impact of central line associated complications**
Serhat Unal (Turkey)
- SP 4-3 **Pitfalls of catheter care in resource-limited settings**
Anucha Apisarnthanarak (Thailand)

10:30-12:00

Room 103

Oral Session 1

Moderators: Hui Wang (China); Yun F Wayne Wang (United States); Hao-Chieh Chiu (Taiwan)

- OS 1-1 **Evaluation of flow cytometry (Sysmex UF1000i) for screening urines for bacteria and white blood cells from patients with suspected urinary tract infection**
Joseph Blondeau (Canada)
- OS 1-2 **Using MALDI-TOF and selected gene (16S rRNA gene, *gyrB* gene) sequencing to practically and accurately identify clinically important viridans group streptococci**
Menglan Zhou (China)
- OS 1-3 **Multiplex PCR assay for identification of *Enterococcus* species on the basis of *groEL* gene**
Wei-Chun Hung (Taiwan)
- OS 1-4 **Comparison of first void urine with urethral swabs for detection of *Ureaplasma* in male patients with urogenital infections by using culture, sequencing, and isothermal RNA amplification assay**
Yali Liu (China)
- OS 1-5 **C-reactive protein levels differ between common respiratory viral infections: role of point-of-care testing in detection of influenza infection**
Angela Chow (Singapore)
- OS 1-6 **Discordance of the vancomycin MIC for methicillin-resistant *Staphylococcus aureus* at 2 µg/mL between Vitek II, E-test, and broth microdilution**
Shin-Yi Tsai (Taiwan)
- OS 1-7 ***Clostridium difficile* MLST clade 4 identification by a simple and reliable MALDI-TOF MS-based method**
Jingwei Cheng (China)
- OS 1-8 **The epidemic severity and the "epidemic potential" of dengue viruses - Taiwan's experiences to help global control**
Chwan-Chuen King (Taiwan)

10:30-12:00

South Lounge

Oral Session 2

Moderators: Jacques F. Meis (Netherlands); Raymond Leung (Hong Kong); Mao-Wang Ho (Taiwan)

- OS 2-1 **Antifungal susceptibility of clinical isolates of 23 genetically confirmed *Aspergillus* species collected from Taiwan and Mainland China**
Ying Li (China)
- OS 2-2 **Proposal of a new scoring system to predict prognosis of Candidaemia patients**
Kazumasa Akagi (Japan)
- OS 2-3 **Antifungal stewardship in a cancer hospital: a pharmacist-led performance improvement programme**
Wei-Ting Chen (Taiwan)
- OS 2-4 **A rare case of *Aspergillus terreus* endogenous endophthalmitis in a non-immunocompromised patient and laboratory research**
Ying Zhao (China)
- OS 2-5 **Epidemiology of candidaemia and antifungal drugs resistance in a teaching hospital in Tangerang, Indonesia**
Cucunawangsih (Indonesia)
- OS 2-6 **The impact of biofilm formation on breakthrough candidaemia**
Wei Sin Li (Taiwan)
- OS 2-7 **MALDI-TOF MS based identification and antifungal susceptibilities of *Trichosporon* isolates causing invasive fungal diseases in China, 2010-2014**
Lina Guo (China)
- OS 2-8 **Anti-herpetic action of ASP2151 (amenamivir) as a helicase-primase inhibitor**
Kimiyasu Shiraki (Japan)

12:15-13:45

Room 201ABC

Satellite Symposium 1

Fungal infection management beyond common IFI

Organised by Gilead Sciences Hong Kong Limited Taiwan Branch

Moderators: Jacques F. Meis (Netherlands); Mao-Wang Ho (Taiwan)

- SS 1-1 **Worldwide azole resistance and clinical implications for antifungal treatment**
Jacques F. Meis (Netherlands)
- SS 1-2 **Management of yeast Infection in blood: Taiwanese experience**
Po-Liang Lu (Taiwan)
- SS 1-3 **Management of a mucormycosis outbreak**
Patrick Chiu Yat Woo (Hong Kong)

12:15-13:45

Room 201DEF

Satellite Symposium 2

Evidence based guidelines: patient assessment and vascular access device selection

Organised by Bard Access Systems

Moderators: Mauro Pittiruti (Italy); Chun-Ming Lee (Taiwan)

- SS 2-1** **Best practice for vascular access device : tips and tricks for better outcomes**
Mauro Pittiruti (Italy)
- SS 2-2** **Expanding the practice of nurses in vascular access - the French experience**
Herve Rosay (France)
- SS 2-3** **Different patients; different vascular device requirement: algorithm to choose the right vascular access device**
Girish V Badarkhe (India)

12:15-13:45

Room 102

Satellite Symposium 3

Influenza update

Organised by Taiwan Shionogi (TS) & Co., Ltd.

Moderators: Shigeru Kohno (Japan); Po-Ren Hsueh (Taiwan)

- SS 3-1** **Global epidemiology and health impact**
Shigeru Kohno (Japan)
- SS 3-2** **Treatment and prevention: what's new?**
Michael G Ison (United States)
- SS 3-3** **Taiwanese perspective**
Wang-Huei Sheng (Taiwan)

12:15-13:45

Room 103

Satellite Symposium 4

Strategy optimisation for complex infection managements in the MDR era

Organised by Pfizer

Moderators: Shan-Chwen Chang (Taiwan); Yee-Chun Chen (Taiwan)

- SS 4-1** **Real-life experience in the treatment of complicated intra-abdominal infections (cIAIs)**
Joseph Solomkin (United States)
- SS 4-2** **Current clinical practice and future developments of the treatment of MRSA pneumonia and skin soft tissue infection**
Jann-Tay Wang (Taiwan)
- SS 4-3** **The rationale for individualized therapy for complex invasive fungal infection**
Deborah Marriott (Australia)

14:00-14:30

Plenary Hall

Keynote Lecture 5

Moderator: Marc Mendelson (South Africa)

Antibiotic stewardship: the reality

Ian M. Gould (United Kingdom)

14:00-14:30

Room 201ABC

Keynote Lecture 6

Moderator: Paul Tambyah (Singapore)

New WHO and CDC guidelines for the prevention of surgical site infections

Joseph Solomkin (United States)

14:00-14:30

Room 201DEF

Keynote Lecture 7

Moderator: TBA

TBA

14:00-14:30

Room 102

Keynote Lecture 8

Moderator: Shan-Chwen Chang (Taiwan)

Emerging zoonotic MERS – CoV disease

Ziad A. Memish (Kingdom of Saudi Arabia)

14:30-16:00**Plenary Hall****Symposium 5****Outpatient parenteral antibiotic therapy; stewardship and right siting in Asia****Co-organised by the ISC OPAT Working Group****Moderators: Visanu Thamlikitkul (Thailand); Cheng-Hua Huang (Taiwan)**

- SP 5-1** **OPAT in Asia**
Dale Fisher (Singapore)
- SP 5-2** **OPAT in the rest of the world**
Mark Gilchrist (United Kingdom)
- SP 5-3** **OPAT – an Indian experience**
Subramanian Swaminathan (India)

14:30-16:00**Room 201ABC****Symposium 6****Antiretroviral resistance: an update****Co-organised by the Taiwan AIDS Society****Moderators: Wasun Chantratita (Thailand); Hsi-Hsun Lin (Taiwan)**

- SP 6-1** **Protease inhibitors in anti-retroviral therapy: past, present and future**
Chloe Orkin (United Kingdom)
- SP 6-2** **Next generation sequencing: a game-changing tool for HIV drug resistance testing in Thailand**
Wasun Chantratita (Thailand)
- SP 6-3** **Current status of antiretroviral resistance in Asia-Pacific region**
Sui-Yuan Chang (Taiwan)

14:30-16:00**Room 201DEF****Symposium 7****Colistin resistance: why? what to do? it is possible to go back?****Moderators: Francesco Scaglione (Italy); Yeu-Jun Lau (Taiwan)**

- SP 7-1** ***Enterobacteriaceae***
Hui Wang (China)
- SP 7-2** ***Acinetobacter* spp.**
Stefania Stefani (Italy)
- SP 7-3** ***mcr*-mediated resistance in animals**
Jean-Marc Rolain (France)

14:30-16:00**Room 102****Symposium 8****Key issues for improving the use of antibiotics****Co-organised by the ISC Antimicrobial Stewardship Working Group****Moderators: Alan Hauser (United States); Shu-Hui Tseng (Taiwan)**

- SP 8-1** **De-escalation of empirical antibiotic treatment: when, how and for whom?**
Pierre Tattevin (France)
- SP 8-2** **Changing behaviour to improve antibiotic stewardship**
Victor Lim (Malaysia)
- SP 8-3** **Rapid blood culture diagnostics to improve antibiotic therapy**
Bert K. Lopansri (United States)

14:30-16:00

Room 103

Oral Session 3

Moderators: Vladimír Krčmery (Slovakia); Chuan-Liang Kao (Taiwan)

- OS 3-1 **Anal HPV in HIV-infected and HIV-uninfected MSM in Guangzhou: implication for vaccination**
Huachun Zou (China)
- OS 3-2 **Correlations between CD4 count, liver function, and renal functions before HAART among CST clients at Sanglah General Hospital, Bali**
Kevin Kristian Putra (Indonesia)
- OS 3-3 **Primary intracranial diffuse large B-cell lymphoma in acquired immune deficiency syndrome patients with previously treated cryptococcal meningitis**
Yukiko Misaki (Japan)
- OS 3-4 **Takeda's candidate tetravalent dengue vaccine (TDV) – progress to phase 3**
Choo Beng Goh (Singapore)
- OS 3-5 **Does seropositivity translate to protection against influenza? - A prospective study among HCWs and patients with chronic respiratory diseases**
Nandhini Palani (India)
- OS 3-6 **Characteristics of immunological failure after 12-month-use of first-line HAART among care support and treatment clients in Sanglah Hospital, Bali Province, Indonesia**
Muhammad Faisal Putro Utomo (Indonesia)
- OS 3-7 **Structural insight into peptidic inhibitors of Zika virus NS2B-NS3 protease**
Congbao Kang (Singapore)
- OS 3-8 **Investigation of occult hepatitis B and C in haemodialysis patients**
Alper Sener (Turkey)

14:30-16:00

South Lounge

Oral Session 4

Moderators: Bo Zheng (China); Wing Hong Seto (Hong Kong); Chun-Kai Huang (Taiwan)

- OS 4-1 **Urinary concentrations and bactericidal activity of tobramycin in healthy subjects receiving a single oral dose (600 Milligrams)**
Florian Wagenlehner (Germany)
- OS 4-2 **Effect of toxin production by antibiotics in multidrug-resistant *Streptococcus pyogenes***
Masaaki Minami (Japan)
- OS 4-3 **Methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to glycopeptides: a 10-year retrospective study**
Katja Seme (Slovenia)
- OS 4-4 **Ceftolozane / tazobactam resistance in *Pseudomonas aeruginosa***
Vincent Tam (United States)
- OS 4-5 **Characterisation of a potential new class of antimicrobial agent for Gram-negative bacteria**
Hongfei Pi (Australia)
- OS 4-6 **High in vitro activity of meropenem/RPX7009 against KPC-producing Enterobacteriaceae in China**
Qiwon Yang (China)
- OS 4-7 **Molecular characterisation of extended spectrum beta-lactamase-producing Gram-negative uropathogens at a specialist hospital in North Western Nigeria**
Tanko Nuhu (Nigeria)

- OS 4-8** **Genotypic variations between wild-type and small colony variants of *Staphylococcus aureus* in prosthetic valve infectious endocarditis: a comparative genomic and transcriptomic analysis**
Jiangang Zhang (China)

16:30-18:00

Plenary Hall

Oral Session 5

Moderators: Mark Gilchrist (United Kingdom); Chien-Hsien Huang (Taiwan)

- OS 5-1** **Implementation of an antibiotic stewardship program in a Tunisian teaching hospital**
Adnene Toumi (Tunisia)
- OS 5-2** **Impact of early antibiotic therapy (EAT) on outcome of patients with sepsis at the emergency room of National Kidney and Transplant Institute**
Irene Rosellen Tan (Philippines)
- OS 5-3** **Compliance with guidelines and appropriateness of antimicrobial prescribing in Australian hospitals**
Rodney James (Australia)
- OS 5-4** **Significance of antimicrobial treatment-related factors for the outcomes of adult empyemas in Japanese tertiary hospitals**
Daisuke Okuno (Japan)
- OS 5-5** **The impact of an antimicrobial stewardship ward round in a cardiovascular surgical intensive care unit**
Ling-Ju Huang (Taiwan)
- OS 5-6** **Appropriateness of surgical prophylaxis contributed to significant reduction of oral cephalosporins in a Japanese university hospital**
Hiroshi Morioka (Japan)
- OS 5-7** **Do prescribers know why they are ordering antibiotics?**
Shermaine Chong (Singapore)
- OS 5-8** **Molecular mechanism and fitness cost of daptomycin resistant *Staphylococcus aureus* obtained from in vitro daptomycin ion pressure**
Yuyao Yin (China)

16:30-18:00

Room 201ABC

Satellite Symposium 5

New era of STR in HIV-1 infection management

Organised by Gilead Sciences Hong Kong Limited Taiwan Branch

Moderators: Chloe Orkin (United Kingdom); Hsi-Hsun Lin (Taiwan) ;

- SS 5-1** **Building the backbone for now and the future; Advancing clinical management in HIV with a novel STR**
Chloe Orkin (United Kingdom)
- SS 5-2** **Early experiences of Genvoya in Hong Kong**
Grace Lui (Hong Kong)
- SS 5-3** **STR perspectives in HIV-1 treatment in Taiwan: from now to the future**
Chien-Ching Hung (Taiwan)

16:30-18:00

Room 201DEF

Oral Session 6

Moderators: Mario Ramirez (Portugal); Chih-Jung Chen (Taiwan)

- OS 6-1 **Phenotypic and genotypic characterisation of ribotype 251 strains of *Clostridium difficile* causing severe disease in the Australian community**
Stacey Hong (Australia)
- OS 6-2 **Timeliness and completeness of molecular screening among populations with a high risk of multidrug resistant tuberculosis in 2010-2015, Taiwan**
Pei-Chun Chan (Taiwan)
- OS 6-3 **First major trichinellosis outbreak in Japan in 35 years**
Katsushige Tada (Japan)
- OS 6-4 **Importance of vaccine serotypes and emergence of non-vaccine serotypes causing non-invasive pneumococcal pneumonia in adults in Portugal (2012-2015)**
Mario Ramirez (Portugal)
- OS 6-5 **The genotype of *Coxiella burnetii* in human Q fever cases is closer to goats than cattle in southern Taiwan**
Chung-Hsu Lai (Taiwan)
- OS 6-6 **Impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia and pneumococcal pneumonia in children in Japan**
Naruhiko Ishiwada (Japan)
- OS 6-7 **Barriers and facilitators to tuberculosis examination among homeless people in Osaka city, Japan**
Chiyoung Hwang (Japan)
- OS 6-8 **Prevalence of mcr-1 in *Escherichia coli* and *Klebsiella pneumoniae* isolated from food animals in four provinces of China**
Ruobing Wang (China)

16:30-18:00

Room 102

Satellite Symposium 6

Leading the fight against MRSA and TB through a cutting edge regimen

Organised by Sanofi Taiwan Co., Ltd.

Moderators: Ian M. Gould (United Kingdom); Min-Chi Lu (Taiwan)

- SS 6-1 **Update on control of MRSA**
Ian M. Gould (United Kingdom)
- SS 6-2 **Glycopeptide selection to treat MRSA infection**
Xiao-Jun Ma (China)
- SS 6-3 **The 3HP regimen in treating latent TB: Taiwan experience sharing**
Hsin-Yun Sun (Taiwan)

16:30-18:00

Room 103

Satellite Symposium 7

Quantitative syphilis diagnostics

Organised by Sekisui Medical Co., Ltd.

Moderators: Kazuhisa Osato (Japan); Jang-Jih Lu (Taiwan)

- SS 7-1** **Mediace RPR/TPLA : Product characteristics and status of use in Japan and Korea**
Osamu Hirata (Japan)
- SS 7-2** **Current status of sexually transmitted disease -focusing on syphilis and serological testing**
Kazuhisa Osato (Japan)
- SS 7-3** **Current developments in sexually transmitted diseases-Focus on Syphilis and serological testing**
Young Joo Cha (Korea)

08:50-09:30

Plenary Hall

Plenary Lecture 3

Moderator: Yin-Ching Chuang (Taiwan)

Zika virus: update

Didier Musso (France)

09:30-10:00

Plenary Hall

Keynote Lecture 9

Moderator: Tzou-Yien Lin (Taiwan)

Vaccines for HPV: the first 10 years

Mario Poljak (Slovenia)

09:30-10:00

Room 201ABC

Keynote Lecture 10

Moderator: Hsieh-Shong Leu (Taiwan)

Infection prevention and quality

Moi Lin Ling (Singapore)

09:30-10:00

Room 201DEF

Keynote Lecture 11

Moderator: Wen-Chien Ko (Taiwan)

***Clostridium difficile*: epidemiology, diversity and evolution in Asia**

Thomas Riley (Australia)

09:30-10:00

Room 102

Keynote Lecture 12

Moderator: Jih-Haw Chou (Taiwan)

Global patterns of MDR-TB evolution

Keira Cohen (United States)

10:30-12:00

Plenary Hall

Symposium 9

Dengue: old disease in children, new disease in adults

Co-organised by the Infectious Disease Association of Thailand (IDAT)

Moderators: Terapong Tantawichien (Thailand); Yhu-Chering Huang (Taiwan)

SP 9-1

Dengue overview: disease and prevention

Usa Thisyakorn (Thailand)

SP 9-2

Dengue in adults and travellers

Terapong Tantawichien (Thailand)

SP 9-3

Dengue vaccines: current clinical perspective

Daniel Goh (Singapore)

10:30-12:00

Symposium 10**HAI prevention and control****Co-organised by the Asia Pacific Society of Infection Control (APSIC)****Moderator: Moi Lin Ling (Singapore); Muh-Yong Yen (Taiwan)**

- SP 10-1** **Control of VAP and CAUTI in Taiwan**
Chun-Ming Lee (Taiwan)
- SP 10-2** **Evidence and pre-requisite for successful prevention of CLABSI**
Anucha Apisarnthanarak (Thailand)
- SP 10-3** **How to prevent HAIs when designing a new hospital**
Glenys Harrington (Australia)

10:30-12:00

Room 201DEF

Symposium 11**Combating antimicrobial resistant pathogens****Co-organised by the Japanese Society of Chemotherapy (JSC)****Moderators: Yoshio Takesue (Japan); Doo-Ryeon Chung (Korea)**

- SP 11-1** **Japan**
Hiroshige Mikamo (Japan)
- SP 11-2** **Korea**
Doo-Ryeon Chung (Korea)
- SP 11-3** **China**
Bo Zheng (China)
- SP 11-4** **New diagnostics for drug resistant pathogens: present and future**
Katsunori Yanagihara (Japan)

10:30-12:00

Room 102

Symposium 12**How to get your paper published****Co-organised by Elsevier****Moderators: Fiona Macnab (United Kingdom); Hsin-Chih Lai (Taiwan)**

- SP 12-1** **What do editors look for?**
John McConnell (United Kingdom)
- SP 12-2** **Frequently asked questions**
Fiona Macnab (United Kingdom)
- SP 12-3** **Ask the editors**
John McConnell (United Kingdom, LID)
Jean-Marc Rolain (France, IJAA)
Stefania Stefani (Italy, JGAR)

10:30-12:00

Oral Session 7

Moderators: Matthew Dryden (United Kingdom); Ming-Li Liou (Taiwan)

- OS 7-1** **Pharmacodynamic comparison of antibiotic activity against *Pseudomonas aeruginosa* in models of persistent infection (intracellular infection, biofilm)**
Paul Tulkens (Belgium)
- OS 7-2** **In vitro activity of cefiderocol against Gram negative clinical isolates collected from Asia and South Pacific in 2014-2016 (SIDERO-CR Study)**
Yoshinori Yamano (Japan)
- OS 7-3** **In vitro activities of cefiderocol (S-649266), ceftazidime-avibactam, ceftolozane-tazobactam, and other comparative drugs against *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* associated with bloodstream infections**
Shun-Chung Hsueh (Taiwan)
- OS 7-4** **Antifungal effect of K21 antimicrobial compound against fluconazole-resistant oral *Candida* isolates from HIV+ patients**
Cathy John (South Africa)
- OS 7-5** **The antimicrobial susceptibility of *Neisseria gonorrhoeae* to faropenem; a carbapenem**
Yoshiki Hiyama (Japan)
- OS 7-6** **A population-based cohort study on the drug specific effect of statins on sepsis outcome**
Meng-Tse Lee (Taiwan)
- OS 7-7** **Treatment strategy against MSSA in our hospital**
Akihisa Nakamura (Japan)
- OS 7-8** ***In vitro* synergistic activities of rifabutin with clarithromycin, imipenem-cilastin and tigecycline against the *Mycobacterium abscessus* complex**
Aristine Cheng (Taiwan)

12:15-13:45

Room 201ABC

Satellite Symposium 8

From empiric therapy to defined treatment

Organised by TTY Biopharm Company Ltd.

Moderators: Ming-Guei Wang (China); Cheng-I Liu (Taiwan)

- SS 8-1** **Empirical treatment for nosocomial pneumonia and intra-abdominal infections**
Ming-Guei Wang (China)
- SS 8-2** **Defined treatment for MRSA and VRE bloodstream infections**
David M. Livermore (United Kingdom)
- SS 8-3** **Defined treatment for MDR-GNB pneumonia and bacteraemia**
Yi-Tsung Lin (Taiwan)

12:15-13:45

Satellite Symposium 9**New insights into empiric antibiotic therapy in respiratory tract infection****Organised by Daiichi Sankyo Co., Ltd.****Moderators: Lionel Ari Mandell (Canada); Yung-Ching Liu (Taiwan)****Epidemiology of hospital-acquired pneumonia: up-to-date data from China***Hui Wang (China)***Recent treatment trend of empiric therapy for severe pneumonia: a perspective from Taiwan***Shih-Chi Ku (Taiwan)***Hospital-acquired pneumonia: what's new in 2017?***Lionel Ari Mandell (Canada)*

12:15-13:45

Room 102

Satellite Symposium 10**Continual immunisation throughout life: from children, adolescents to adults****Organised by Sanofi Taiwan Co., Ltd.****Moderators: Daniel Goh Yam Thiam (Singapore); Tzou-Yien Lin (Taiwan)****SS 10-1 Pertussis among adolescents and adults***Cheng-Hsun Chiu (Taiwan)***SS 10-2 Shifting epidemiology of Japanese encephalitis: the importance of adult boosters***Hee Soo Kim (South Korea)***SS 10-3 Extra protection against influenza: quadrivalent influenza vaccines***Daniel Goh Yam Thiam (Singapore)*

12:15-13:45

Room 103

Satellite Symposium 11**Laboratory diagnostics of sepsis****Organised by Becton Dickinson Company****Moderators: Wing Hong Seto (Hong Kong); Kao-Pin Hwang (Taiwan)****SS 11-1 Using informatics to optimise sepsis diagnosis workflow***Yun F (Wayne) Wang (USA)***SS 11-2 Blood volume and blood culture positive rates***Raymond Leung (Hong Kong)***SS 11-3 A new era for infection control: molecular diagnosis***Yu-Jiun Chan (Taiwan)*

14:00-14:30 **Plenary Hall**

Keynote Lecture 13

Moderator: Serhat Unal (Turkey)

Antimicrobial stewardship practice in Taiwan

Yin-Ching Chuang (Taiwan)

14:00-14:30 **Room 201ABC**

Keynote Lecture 14

Moderator: TBA

TBA

14:00-14:30 **Room 201DEF**

Keynote Lecture 15

Moderator: Jen-Jyh Lee (Taiwan)

MDR/XDR TB treatment update

Chen-Yuan Chiang (IUAT)

14:00-14:30 **Room 102**

Keynote Lecture 16

Moderator: Chun-Ming Lee (Taiwan)

Reactive oxygen therapy, a serious antibiotic alternative?

Matthew Dryden (United Kingdom)

14:30-16:00 **Plenary Hall**

Symposium 13

Drug resistance in the microbial world

Co-organised by the European Society of Clinical Microbiology and Infectious Disease (ESCMID)

Moderators: Mario Poljak (Slovenia); Jen-Ren Wang (Taiwan)

- SP 13-1** **Antibacterial resistance: current status and future perspectives**
Giuseppe Cornaglia (Italy)
- SP 13-2** **Antiviral resistance: new drugs, new problems?**
Mario Poljak (Slovenia)
- SP 13-3** **Beyond antibiotics: new therapeutic approaches for bacterial infections**
Alan Hauser (United States)

14:30-16:00 **Room 201ABC**

Symposium 14

The expanding global problem of antifungal resistance

Co-organised by the ISC Infection Prevention and Control Working Group

Moderators: TBA; Jien-Wei Liu (Taiwan)

- SP 14-1** **Azole resistance in *Aspergillus fumigatus***
Jacques F. Meis (Netherlands)
- SP 14-2** **Emerging resistance in *Candida***
Yee-Chun Chen (Taiwan)
- SP 14-3** **Rare fungal pathogens beyond *Aspergillus* and *Candida***
Anuradha Chowdhary (India)

14:30-16:00

Room 201DEF

Symposium 15**Antimicrobial stewardship in Asia**

Co-organised by the Japanese Society of Chemotherapy (JSC)

Moderators: Hiroshi Kiyota (Japan); Vincent Cheng (Hong Kong)

- SP 15-1 **Japan**
Satoshi Takahashi (Japan)
- SP 15-2 **Korea**
Hyungmin Lee (Korea)
- SP 15-3 **Singapore**
David Chien Boon Lye (Singapore)
- SP 15-4 **Development of new antibiotics**
Kazuhiro Tateda (Japan)

14:30-16:00

Room 102

Symposium 16**Infections/outbreaks and the world refugee crisis**

Co-organised by the ISC Working Group on Infections in Catastrophic Areas

Moderators: Didier Musso (France); Wing-Wai Wong (Taiwan)

- SP 16-1 **Lessons from South Sudan: tribal conflicts and outbreaks of infectious diseases internally displace populations**
Andrea Shahum (Cambodia)
- SP 16-2 **Screening of HIV, TB, HBV among migrants on the Balkan route**
Vladimir Krcmery (Slovakia)
- SP 16-3 **Vaccination and war conflicts in Lebanon, Syria and Iraq**
Jozef Suvada (Lebanon)

14:30-16:00

Room 103

Oral Session 8

Moderators: Subramanian Swaminathan (India); Chi-Shih Chu (Taiwan)

- OS 8-1 **Capsular serotype and polysaccharide production in hyper-virulent *K. pneumoniae* strains from bacteraemias in Japan**
Atsushi Togawa (Japan)
- OS 8-2 **Placental macrophages in HIV-1-infected women receiving highly active anti-retroviral therapy (HAART): immunohistochemical evidence of protective role in materno-foetal HIV transmission**
Moses Kapembwa (United Kingdom)
- OS 8-3 **Sensitivity of MRSA isolates for ultra-diluted homeopathic medicines in in-vitro conditions**
Ganesh Lakshmanan (India)
- OS 8-4 **Comparative analysis of large clostridial toxin negative, CDT producing *C. difficile* strains**
Grace O Androga (Australia)
- OS 8-5 **Pathogenic role of stringent response in oxidative stress response and biofilm formation of *Helicobacter pylori***
Shigeru Kamiya (Japan)

- OS 8-6** **Chimeric virulence and antimicrobial-resistant plasmid pOU7519 in *Salmonella enteritica* serovar Choleraesuis**
Chyi-Liang Chen (Taiwan)
- OS 8-7** **Solithromycin inhibits MUC5AC production induced by *Streptococcus pneumoniae* and *Haemophilus influenzae* in human airway epithelial cells**
Kenji Ota (Japan)

14:30-16:00

South Lounge

Oral Session 9

Moderators: Susan S Huang (United States); Yuarn-Jang Lee (Taiwan)

- OS 9-1** **Long term effects of oral antibiotic prophylaxis for colorectal surgery on the frequencies and trends of bacteria isolated from patients in a surgical ward**
Hiroaki Hata (Japan)
- OS 9-2** **Association between positive culture results during admission and one-year mortality in critically ill cancer patients**
Hsiu-Yin Chiang (Taiwan)
- OS 9-3** **Strict glycaemic control to prevent surgical site infections in gastroenterology surgery in patients with and without diabetes mellitus**
Toshie Tsuchida (Japan)
- OS 9-4** **Effectiveness of antibacterial linen in prevention of hospital acquired infections**
Trang Dang Thi Van (Vietnam)
- OS 9-5** **Administration of antimicrobials affects the nasal bacterial flora in ICU patients**
Shuichi Abe (Japan)
- OS 9-6** **Retrospective analysis of antibacterial treatment for infectious disease of elderly and very elderly patients**
Kazuki Taoka (Japan)
- OS 9-7** **Tracking a nosocomial Carbapenem-Resistant *Klebsiella Pneumoniae* outbreak by whole-genome sequencing**
Qi Wang (China)

16:30-18:00

Plenary Hall

Oral Session 10

Moderators: Paul Tulkens (Belgium); Susan Shin-Jung Lee (Taiwan)

- OS 10-1** ***Campylobacter fetus*-infected aneurysm: case report and literature review 1971–2016**
Kiyozumi Suzuki (Japan)
- OS 10-2** ***Staphylococcus argenteus*, an emerging pathogen of community-onset bacteraemia associated with high mortality**
Chien-Yu Chi (Taiwan)
- OS 10-3** **Bacteraemia in patients over 90 years of age**
Yuji Hirai (Japan)
- OS 10-4** **β -lactams versus glycopeptides for the treatment of *Enterococcus faecalis* bacteraemia**
Yu-Ping Wang (Taiwan)
- OS 10-5** **Cerebral syphilitic gumma can arise within months of re-infection: a case of histologically proved *Treponema pallidum* strain type 14b/f infection with HIV positivity**
Yusuke Koizumi (Japan)

- OS 10-6** **Clinical characteristics, microbiology and outcomes of patients with severe influenza during the 2016 flu endemic in Taiwan**
Ching-Yuan Yeh (Taiwan)
- OS 10-7** ***Corynebacterium* blood stream infection among haematological malignancy patients with neutropenia: a case series analysis**
Hiroyuki Takahashi (Japan)
- OS 10-8** **Role of environmental surveillance in communal areas after a hospital outbreak of multidrug-resistant *Acinetobacter baumannii* in Hong Kong**
Shuk Ching Wong (Hong Kong)

16:30-18:00

Room 201ABC

Satellite Symposium 12

Critical Gram-negative MDRs - a clinical update

Organised by MSD

Moderators: Tony Korman (Australia), Yin-Ching Chuang (Taiwan)

- SS 12-1** **Antibiotic-Resistant Gram Negative Bacteria in Asia: Catch me if you can**
Visanu Thamlikitkul (Thailand)
- SS 12-2** **Beta lactam - beta lactamase inhibitors (BL- BLIs) – what is their role in antimicrobial stewardship?**
Tony Korman (Australia)
- SS 12-3** **Empiric therapy in cIAI-cUTI: what is needed to get it right?**
Rontgene M. Solante (Philippines)

16:30-18:00

Room 201DEF

Oral Session 11

Moderators: Hiroshige Mikamo (Japan); Lih-Shinn Wang (Taiwan)

- OS 11-1** **Contribution of horizontal gene transfer to the spread of VIM-4 carbapenemase producer *Enterobacteriaceae* in Kuwait**
Agnes Sonnevend (United Arab Emirates)
- OS 11-2** **Ampicillin plus ceftriaxone could safely treat infective endocarditis caused by *Enterococcus faecalis***
Hanako Yoshihara (Japan)
- OS 11-3** **The emergence of *Klebsiella pneumoniae* ST14, ST147 and ST231 clones among carbapenem-resistant *Enterobacteriaceae* isolated between 2009 and 2015 in Abu Dhabi, UAE**
Tibor Pal (United Arab Emirates)
- OS 11-4** **Genome wide dissection of *S. pneumoniae* non-susceptible to a wide range of β -lactam antibiotics, circulating among preschool children in central Vietnam**
Hiroshi Fujii (Japan)
- OS 11-5** **The emergence of hyper virulent and antimicrobial-resistant capsular type K1 *Klebsiella pneumoniae* strains in Taiwan**
Yi-Tsung Lin (Taiwan)
- OS 11-6** **Is there a global increase in resistance to antibiotics? A snapshot of resistance from 2014 to 2016 in Marseille, France**
Stephanie Le Page (France)

16:30-18:00

Room 102

Satellite Symposium 13

Microbiota and probiotics

Organised by Maywufa

Moderators: Kazuhiro Tateda (Japan); Yen-Hsu Chen (Taiwan)

Probiotics in Taiwan from bench to clinical

Chun-Yan Yeung (Taiwan)

The role of probiotics in the control and prevention of MDROs

Shey-Ying Chen (Taiwan)

***C. difficile* infection**

Kazuhiro Tateda (Japan)

16:30-18:00

Room 103

Satellite Symposium 14

Latest improvement of automated environmental control in approaching zero tolerance of healthcare-associated infection

Organised by Chriskey Biomedical Technology Corporation

Moderators: Victor Lim (Malaysia); Wen-Sen Lee (Taiwan)

SS 14-1 Environmental associated MDRO nosocomial infections

Victor Lim (Malaysia)

SS 14-2 Significance of environmental decontamination

Ping-Ing Lee (Taiwan)

SS 14-3 Nanotechnology in environmental disinfection

Muh-Yong Yen (Taiwan)

Monday, 27 November

08:50-09:30

Plenary Hall

Plenary Lecture 4

Moderator: Lee-Jene Teng (Taiwan)

Novel technologies and diagnostic methods in AMR era

Kazuhiro Tateda (Japan)

09:30-10:00

Plenary Hall

Keynote Lecture 17

Moderator: Raphael Saginur (Canada)

Antibiotic resistance has a language problem

Marc Mendelson (South Africa)

09:30-10:00

Room 201ABC

Keynote Lecture 18

Moderator: Cheng-Hsun Chiu (Taiwan)

Vaccines for travel, vaccines for adults: moving targets!

David Mcintosh (United Kingdom)

09:30-10:00

Room 201DEF

Keynote Lecture 19

Moderator: Yen-Hsu Chen (Taiwan)

Reducing device associated infections – the case of catheter associated urinary tract infections

Paul Tambyah (Singapore)

09:30-10:00

Room 102

Keynote Lecture 20

Moderator: Ching-Chuan Liu (Taiwan)

Viral and host factors involved in enterovirus 71 infection – potential applications in therapy and prophylaxis

Shin-Ru Shih (Taiwan)

10:30-12:00

Plenary Hall

Symposium 17

Emerging zoonotic viral infections: MERS, swine, equine, and canine influenza and Zika

Co-organised by the ISC Zoonoses Working Group

Moderators: Alfonso J. Rodriguez-Morales (Colombia); Po-Yen Chen (Taiwan)

SP 17-1

MERS-CoV and mass gathering events

Ziad A. Memish (Kingdom of Saudi Arabia)

SP 17-2

Swine, equine, and canine influenza: should we consider changes in these virus as public health threats?

Yi-Chun Lo (Taiwan)

SP 17-3

Zika: epidemiology, complications and the experience in Latin America

Alfonso J. Rodriguez-Morales (Colombia)

10:30-12:00

Room 201ABC

Symposium 18State-of-the art: *Pneumococcal* diseases and vaccination

Co-organised by the ISC Vaccines Working Group

Moderators: David Mcintosh (United Kingdom); Li-Min Huang (Taiwan)

SP 18-1 Global burden of *Pneumococcal* diseases*Mario Ramirez (Portugal)***SP 18-2 *Pneumococcal* vaccination in Asia: current status***Ping-Ing Lee (Taiwan)***SP 18-3 *Pneumococcal* vaccines for adults***Atef M. Shibl (Saudi Arabia)*

10:30-12:00

Room 201DEF

Symposium 19

Using PK/PD to optimise therapy

Co-organised by the ISC Infections in the ICU and Sepsis Working Group

Moderators: Pierre Tattevin (France); Chang-Pan Liu (Taiwan)

SP 19-1 Antibiotic dosing in patients receiving RRT and ECMO*Francesco Scaglione (Italy)***SP 19-2 TDM and pharmacokinetics of triazoles***Shu-Wen Lin (Taiwan)***SP 19-3 Population pharmacokinetic and pharmacodynamics analyses of glycopeptides**

TBA

10:30-12:00

Room 102

Symposium 20

Hot topics in urogenital tract infections

Co-organised by the ISC UTI Working Group

Moderators: Florian Wagenlehner (Germany); Stephen Yang (Taiwan)

SP 20-1 Antibiotic resistance is a major problem in the management of urogenital infections*Shingo Yamamoto (Japan)***SP 20-2 Novel antibiotics in the treatment of urinary tract infections***Florian Wagenlehner (Germany)***SP 20-3 Are UTI managed differently in Asia, Europe and America?***Seung-Ju Lee (South Korea)***SP 20-4 Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial***Ildikó Gágyor (Germany)*

10:30-12:00

Room 103

Oral Session 12

Moderators: Glenys Harrington (Australia); Zhi-Yuan Shi (Taiwan)

- OS 12-1 **STEREX® S: A novel efficient disinfectant formulation against antibiotic-resistant microbial pathogens**
Chalermpong Saenjum (Thailand)
- OS 12-2 **Challenges and successes: TB infection control programme implementation at an academic medical centre in Saudi Arabia: a multidisciplinary process improvement project**
Ashraf Khan (Saudi Arabia)
- OS 12-3 **Risk factors and molecular epidemiology of *Acinetobacter baumannii* bacteraemia in neonates**
Hao-Yuan Lee (Taiwan)
- OS 12-4 **Central nervous system complications in infective endocarditis; serum ferritin levels can be a simple predictor?**
Yuji Hirai (Japan)
- OS 12-5 **Characterization of rifampin-resistant *Staphylococcus aureus* nasal carriage in patients receiving rifampin-containing regimens for tuberculosis**
Yu-Tsung Huang (Taiwan)
- OS 12-6 **Aetiology of CNS infections in Nepal using the FilmArray meningitis/encephalitis panel**
Olof Sall (Sweden)

10:30-12:00

South Lounge

Oral Session 13

Moderators: Raphael Saginur (Canada); Luan-Yin Chang (Taiwan)

- OS 13-1 **Impact of inappropriate empiric antibiotic therapy on the mortality in paediatric patients with bloodstream infections**
Michihito Kyo (Japan)
- OS 13-2 **Acute gastroenteritis in hospitalised children in southern Taiwan: emphasis on *Clostridium difficile* related acute gastroenteritis**
Fu- Chun Kuo (Taiwan)
- OS 13-3 **Impact of infectious diseases consultation within 10 days and outcome of length of inpatient hospital stay among patients with infective endocarditis**
Yuichi Takahashi (Japan)
- OS 13-4 **Adenovirus detection in paediatric community acquired pneumonia in Taiwan during 2010 to 2015**
Ching-Fen Shen (Taiwan)
- OS 13-5 **Changes in quinolone susceptibility of *Streptococcus pneumoniae* isolated from community-acquired pneumococcal pneumonia in children <5 years of age: influence of oral fluoroquinolone granules for children in Japan**
Noriko Takeuchi (Japan)
- OS 13-6 **Extended-spectrum β -lactamase-producing *Escherichia coli* bacteraemia: comparison of paediatric and adult populations**
Ming-Fang Cheng (Taiwan)